Kopran
NSE: KOPRAN · Pharmaceuticals
Snapshot
Unlock Kopran's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Kopran Limited is an integrated pharmaceutical company engaged in the manufacturing and sale of active pharmaceutical ingredients (APIs) and finished dosage forms. The company offers a diverse portfolio of products, including tablets, capsules, injectables, and various therapeutic categories such as cardiovascular and anti-infective treatments.
Business Model
The company generates revenue by manufacturing and distributing pharmaceutical products across domestic and international markets. Its business model relies on an integrated supply chain that spans from the production of raw APIs to the final delivery of finished dosage forms.
- Incorporation Year:1958
Growth Outlook
Growth is driven by the company's extensive therapeutic portfolio and its ability to supply both APIs and finished formulations globally. Continued expansion into diverse dosage forms and international markets remains a key strategic focus.
Key Risks
- Regulatory Compliance. The company is subject to stringent global pharmaceutical regulations, where non-compliance could lead to manufacturing bans or product recalls.
- Raw Material Price Volatility. Fluctuations in the cost of active pharmaceutical ingredients and raw materials can significantly impact profit margins.
- Foreign Exchange Risk. As an international exporter, the company is exposed to currency fluctuations that may affect its export competitiveness and financial performance.
- Intense Competition. The pharmaceutical sector is highly competitive, with pricing pressures from both domestic and international generic drug manufacturers.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Kopran and 5,000+ companies — free.
Key Metrics
REVENUE
₹681 Cr
TTM · consolidated
NET PROFIT
₹26 Cr
TTM · consolidated
EPS
₹5.32
TTM · consolidated
RETURN ON EQUITY
4.9%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
7.7%
TTM · consolidated
P/E
38.3x
Q4 FY26 · consolidated
EV/EBITDA
18.2x
Q4 FY26 · consolidated
EBITDA MARGIN
9.1%
TTM · consolidated
NET PROFIT MARGIN
8.1%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.3x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
KopranKOPRAN | 561 | 38.27 | 18.22 | 8.2% | 9.1% | 4.9% | 7.7% | +12.4% |
Themis MedicareTHEMISMED | 663 | 864.77 | 116.11 | -15.6% | 2.8% | 0.3% | -0.3% | -9.9% |
Shree Ganesh RemSGRL | 624 | 47.05 | 22.40 | — | 34.8% | 11.9% | 15.9% | +7.6% |
Anlon HealthcareAHCL | 605 | 1.97 | 13.92 | — | 26.3% | 13.3% | 20.9% | — |
Influx Health.INFLUX | 508 | — | — | — | 20.0% | — | — | +79.7% |
Jenburkt PharmaJENBURPH | 451 | 13.84 | 8.79 | — | 32.0% | 17.6% | 23.2% | -15.6% |
As of Q4 FY26
Financials
Kopran
NSE: KOPRAN · Pharmaceuticals
Snapshot
Unlock Kopran's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Kopran Limited is an integrated pharmaceutical company engaged in the manufacturing and sale of active pharmaceutical ingredients (APIs) and finished dosage forms. The company offers a diverse portfolio of products, including tablets, capsules, injectables, and various therapeutic categories such as cardiovascular and anti-infective treatments.
Business Model
The company generates revenue by manufacturing and distributing pharmaceutical products across domestic and international markets. Its business model relies on an integrated supply chain that spans from the production of raw APIs to the final delivery of finished dosage forms.
- Incorporation Year:1958
Growth Outlook
Growth is driven by the company's extensive therapeutic portfolio and its ability to supply both APIs and finished formulations globally. Continued expansion into diverse dosage forms and international markets remains a key strategic focus.
Key Risks
- Regulatory Compliance. The company is subject to stringent global pharmaceutical regulations, where non-compliance could lead to manufacturing bans or product recalls.
- Raw Material Price Volatility. Fluctuations in the cost of active pharmaceutical ingredients and raw materials can significantly impact profit margins.
- Foreign Exchange Risk. As an international exporter, the company is exposed to currency fluctuations that may affect its export competitiveness and financial performance.
- Intense Competition. The pharmaceutical sector is highly competitive, with pricing pressures from both domestic and international generic drug manufacturers.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Kopran and 5,000+ companies — free.
Key Metrics
REVENUE
₹681 Cr
TTM · consolidated
NET PROFIT
₹26 Cr
TTM · consolidated
EPS
₹5.32
TTM · consolidated
RETURN ON EQUITY
4.9%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
7.7%
TTM · consolidated
P/E
38.3x
Q4 FY26 · consolidated
EV/EBITDA
18.2x
Q4 FY26 · consolidated
EBITDA MARGIN
9.1%
TTM · consolidated
NET PROFIT MARGIN
8.1%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.3x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26